Published by Iain Gilbert on 29th June 2026
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first‑line monotherapy for adults with unresectable or metastatic triple‑negative breast cancer who are not eligible for PD‑1/PD‑L1 inhibitor treatment.